The FDA has approved the first ever RNA interference drug – Alnylam’s Onpattro (patisiran) for the nerve damage caused by the rare disease hereditary transthyretin-mediated amyloidosis (hATTR ...

Alnylam expects combined net product revenues from Onpattro, Amvuttra, Givlaari and Oxlumo in the range of $2.05-$2.25 billion in 2025, implying a combined full-year growth of 31% at the mid-point ...

2025 Combined Net Product Revenue & Non-GAAP Operating Income Guidance Alnylam announced today full year 2025 combined net product revenue guidance for ONPATTRO, AMVUTTRA (PN & CM**), GIVLAARI and ...

ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO.

said it made about $343 million in net product revenue from its Onpattro and Amvuttra products in the fourth quarter of 2024, based on preliminary numbers published Sunday. Alnylam expects those ...

Alnylam announced full year 2025 combined net product revenue guidance for ONPATTRO, AMVUTTRA (PN & CM), GIVLAARI and OXLUMO of $2.050 billion to $2.250 billion, representing combined full year ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

Alnylam Pharmaceuticals ALNY announced preliminary net product revenues for the fourth quarter and full-year 2024 for its approved products Onpattro (patisiran), Amvuttra (vutrisiran), Givlaari ...

Alnylam Pharmaceuticals ALNY announced preliminary net product revenues for the fourth quarter and full-year 2024 for its approved products Onpattro (patisiran), Amvuttra (vutrisiran), Givlaari ...